Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003590 · ClinicalTrials.gov registry record · Phase 2
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
A Phase 2 study of Adult Meningioma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT00003590: Completed Phase 2 study of Adult Meningioma, sponsored by SWOG Cancer Research Network.
NCT00003590 is a Phase 2 study of Adult Meningioma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003590, a Phase 2 study of Adult Meningioma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.
Primary Outcome
Complete Response (CR)is a complete disappearance of all measurable and evaluable disease. No new lesions, no disease related symptoms, no evidence of non-evaluable disease. Partial Response (PR)is greater than or equal to 50% decrease under baseline in sum of the products of perpendicular diameters of all measurable lesions. No progression of evaluable disease, no new lesions. Confirmation of CR or PR means a repeat scan at least 3 weeks apart documented before progression. No response means th
Conditions Studied
Interventions
- DRUG hydroxyurea
Study Locations (20)
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora
- St. Anthony Central Hospital - Denver
- Denver Health Medical Center - Denver
- Veterans Affairs Medical Center - Denver - Denver
- Montrose Memorial Hospital Cancer Center - Montrose
- St. Anthony North Hospital - Westminster
- Exempla Lutheran Medical Center - Wheat Ridge
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
California
- City of Hope Comprehensive Cancer Center - Duarte
- CCOP - Bay Area Tumor Institute - Oakland
- University of California Davis Cancer Center - Sacramento
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- CCOP - Western Regional, Arizona - Phoenix
Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Florida
- M.D. Anderson Cancer Center - Orlando - Orlando
Idaho
- North Idaho Cancer Center - Coeur d'Alene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1998-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT00003590 record still lists
NCT00003590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Adult Meningioma appearing as the primary indexed condition, and to 1 intervention - of which hydroxyurea is the first listed.
NCT00003590 names 20 study sites across 8 states, led by Colorado, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00003590 about?
NCT00003590 is a clinical study titled "S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma". RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.
What is the current status of trial NCT00003590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 1998-11. Estimated completion is 2011-07.
What conditions does trial NCT00003590 study?
This clinical trial studies the following conditions: Adult Meningioma.
What interventions are being tested in trial NCT00003590?
The interventions under investigation include: hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00003590?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003590 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003590's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia